Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients
- First Posted Date
- 2009-08-26
- Last Posted Date
- 2016-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 87
- Registration Number
- NCT00966277
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Caphosol in Sarcoma Patients With Mucositis
Phase 2
Completed
- Conditions
- SarcomaOral Mucositis
- Interventions
- Other: CaphosolOther: Baking Soda
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2012-03-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00965172
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2016-09-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 53
- Registration Number
- NCT00965341
- Locations
- 🇺🇸
The DeBakey VA Medical Center/Baylor College of Medicine, Houston, Texas, United States
🇺🇸UT MD Anderson Cancer Center, Houston, Texas, United States
Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Transitional Cell Carcinoma of the Bladder
Phase 2
Completed
- Conditions
- Bladder Cancer
- Interventions
- Procedure: Robotic-assisted laparoscopic surgery
- First Posted Date
- 2009-08-24
- Last Posted Date
- 2013-05-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT00963859
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia
Phase 1
Withdrawn
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Biological: Influenza Vaccine Trivalent Inactivated (TIV)Drug: Pegylated interferon (PEGrIFN-α, Pegasys)Drug: Interferon (IFNα, Roferon-A)
- First Posted Date
- 2009-08-20
- Last Posted Date
- 2012-08-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00962715
Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist
Phase 2
Completed
- Conditions
- Melanoma
- Interventions
- Drug: gp100Drug: R848 gelDrug: MAGE-3
- First Posted Date
- 2009-08-18
- Last Posted Date
- 2021-08-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 47
- Registration Number
- NCT00960752
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
NOV-002 in Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2009-08-18
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00960726
Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism
- First Posted Date
- 2009-08-18
- Last Posted Date
- 2019-06-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00960544
Study of Bortezomib in Combination With Cyclophosphamide and Rituximab
Phase 2
Completed
- Conditions
- LymphomaMantle Cell Lymphoma
- Interventions
- First Posted Date
- 2009-08-13
- Last Posted Date
- 2015-04-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT00958256
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Preoperative Treatment With Cetuximab and/or IMC-A12
Phase 2
Completed
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2009-08-13
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT00957853
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath